The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The role of C-reactive protein (CRP) as a prognostic biomarker in patients with early breast cancer (EBC) treated with neoadjuvant chemotherapy (NACT).
 
Hans-Christian Kolberg
Stock and Other Ownership Interests - Phaon Scientific; Theraclion
Honoraria - Amgen; AstraZeneca; Carl Zeiss Meditec; Genomic Health; MSD Oncology; Novartis; Onkowissen; Pfizer; Roche; SurgVision; Theraclion; Theramex
Consulting or Advisory Role - Amgen; SurgVision
Travel, Accommodations, Expenses - Amgen; Carl Zeiss Meditec; Daiichi Sankyo; Genomic Health; LIV Pharma; Novartis; Pfizer; Roche; Tesaro
 
Alexandra Edimiris
No Relationships to Disclose
 
Oliver Hoffmann
Consulting or Advisory Role - Hexal; MSD; Novartis; Roche
 
Sarah Wetzig
No Relationships to Disclose
 
Mohamed Shaheen
No Relationships to Disclose
 
Miltiades Stephanou
No Relationships to Disclose
 
Cornelia Kolberg-Liedtke
Employment - Palleos
Stock and Other Ownership Interests - Phaon Scientific (I); Theraclion (I)
Honoraria - Amgen; Amgen (I); AstraZeneca; AstraZeneca (I); Carl Zeiss Meditec (I); Celgene; Genomic Health (I); GlaxoSmithKline (I); HEXAL; Janssen-Cilag (I); Lilly; LIV Pharma (I); Novartis; Novartis (I); Pfizer; Pfizer (I); RIEMSER (I); Roche; Roche (I); SonoScape; Teva (I); Teva (I); Theraclion (I)
Consulting or Advisory Role - Amgen (I); Carl Zeiss Meditec (I); Celgene; Novartis; Novartis (I); Onkowissen (I); Pfizer; Pfizer (I); Phaon Scientific; Roche; SurgVision (I)
Research Funding - Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Amgen (I); Carl Zeiss Meditec (I); Daiichi Sankyo; Daiichi Sankyo (I); LIV Pharma (I); Novartis; Novartis (I); Pfizer (I); Roche